PubMed Central (PMC) Search Page
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 1971 | 1 |
| 1973 | 1 |
| 1997 | 1 |
| 1999 | 1 |
| 2000 | 2 |
| 2002 | 3 |
| 2003 | 2 |
| 2004 | 4 |
| 2005 | 5 |
| 2006 | 13 |
| 2007 | 23 |
| 2008 | 49 |
| 2009 | 69 |
| 2010 | 67 |
| 2011 | 58 |
| 2012 | 64 |
| 2013 | 77 |
| 2014 | 76 |
| 2015 | 78 |
| 2016 | 107 |
| 2017 | 101 |
| 2018 | 132 |
| 2019 | 178 |
| 2020 | 169 |
| 2021 | 263 |
| 2022 | 189 |
| 2023 | 96 |
| 2024 | 151 |
| 2025 | 147 |
| 2026 | 143 |
-
Publication date
-
-
Publication stage
These filters represent the three primary types of content included in the PMC archive: 1) content published in a scholarly journal 2) peer-reviewed author manuscripts accepted for publication in a journal and 3) preprint versions of articles collected through the NIH Preprint Pilot, made public prior to peer review
-
-
Collections
The PMC Open Access Subset includes journal articles and preprints that are made available under license terms that allow reuse. Historical back issues refers to digitized content from print journals made available in PMC through the Biomedical Journal Digitization Projects.
-
"J Nucl Med"[Journal]
The embargo is the time during which the publisher retains exclusive rights to distribute articles. Those articles are made freely available on the PMC website after the embargo period has ended. Citations for articles under an embargo period will still display in the PMC results list by default. Choose “Exclude” to prevent embargoed articles from displaying in your results.
-
LASER: A Phase 2 Trial of 177Lu-PSMA-617 as Systemic Therapy for RCC.
- Hazut Krauthammer S, Xie W, LaBrecque N, Arsenault L, Kabarame L, Shah H, Berg S, McGregor B, Serzan M, Xu W, Viswanathan SR, Wei XX, Choueiri TK, Jacene H, Ravi P.
- J Nucl Med. 2026 Apr 1;67(4):501-505. doi: 10.2967/jnumed.125.271273.
- PMCID: PMC13670995
Hazut Krauthammer S, et al.J Nucl Med. 2026.PMCID: PMC13670995 -
First-in-Human Study of the Carbohydrate Nanoparticle 64Cu-Macrin.
- O'Shea A, Lewis AJM, Caravan P, Izquierdo-Garcia D, Le Fur M, Catalano OA, Montesi SB, Quintana JM, Carlson JCT, Dubach JM, Castro CM, Bobić M, Huesa-Berral C, Ng TSC, Bertolet A, Nahrendorf M, Weissleder R.
- J Nucl Med. 2026 Mar 2;67(3):449-455. doi: 10.2967/jnumed.125.270770.
- PMCID: PMC13671009
O'Shea A, et al.J Nucl Med. 2026.PMCID: PMC13671009 -
The Role of Amyloid-β and Tau PET in the New Era of Alzheimer Disease Therapies.
- Chiotis K, Wang Y, La Joie R, Rabinovici GD.
- J Nucl Med. 2026 Feb 2;67(2):175-185. doi: 10.2967/jnumed.124.268339.
- PMCID: PMC13671013
Chiotis K, et al.J Nucl Med. 2026.PMCID: PMC13671013 -
Diuresis During 18F-Flotufolastat (rhPSMA-7.3) PET/CT Improves Recurrence Detection After Prostatectomy: A Prospective Phase II Trial.
- Lawal IO, Mushtaq A, Jani AB, Rupji M, Dhere VR, Patel SA, Bilen MA, Patel PR, Sebastian NT, Switchenko JM, Schuster DM, Marcus C.
- J Nucl Med. 2025 Feb 3;66(2):230-237. doi: 10.2967/jnumed.124.268574.
- PMCID: PMC13671398
Lawal IO, et al.J Nucl Med. 2025.PMCID: PMC13671398 -
Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET-An International Multicenter Retrospective Study.
- Unterrainer LM, Hope TA, Fendler WP, Grogan T, Ndlovu H, Armstrong W, Barbato F, Benz MR, Rettig MB, Kishan AU, Sathekge M, Herrmann K, Czernin J, Calais J.
- J Nucl Med. 2025 Jan 3;66(1):54-60. doi: 10.2967/jnumed.124.268441.
- PMCID: PMC13671395
Unterrainer LM, et al.J Nucl Med. 2025.PMCID: PMC13671395 -
[18F]Fluorthanatrace PET in Ovarian Cancer: Comparison with [18F]FDG PET, Lesion Location, Tumor Grade, and Breast Cancer Gene Mutation Status.
- Weeks JK, Pantel AR, Gitto SB, Liu F, Schubert EK, Pryma DA, Farwell MD, Mankoff DA, Mach RH, Simpkins F, Lin LL.
- J Nucl Med. 2025 Jan 3;66(1):34-39. doi: 10.2967/jnumed.124.267627.
- PMCID: PMC13671396
Weeks JK, et al.J Nucl Med. 2025.PMCID: PMC13671396 -
Cardiac Neuroendocrine Tumor Metastases on 68Ga-DOTATATE PET/CT: Identification and Prognostic Significance.
- Lee H, Alhamshari AS, Patel V, Bhattaru A, Rojulpote C, Vidula MK, Pryma DA, Bravo PE.
- J Nucl Med. 2024 Nov 1;65(11):1745-1753. doi: 10.2967/jnumed.124.267948.
- PMCID: PMC13671382
Lee H, et al.J Nucl Med. 2024.PMCID: PMC13671382 -
Initial Experience with [177Lu]Lu-PSMA-617 After Regulatory Approval for Metastatic Castration-Resistant Prostate Cancer: Efficacy, Safety, and Outcome Prediction.
- Gafita A, Voter A, Shesadri S, Spitz A, Marshall CH, Rowe SP, Markowski MC, Pomper MG, Civelek AC, Carducci MA, Denmeade SR, Young J, Pienta KJ, Paller CJ, Solnes LB.
- J Nucl Med. 2024 Nov 1;65(11):1724-1730. doi: 10.2967/jnumed.124.267723.
- PMCID: PMC13671383
Gafita A, et al.J Nucl Med. 2024.PMCID: PMC13671383 -
Impact of Posttreatment SPECT/CT on Patient Management During 177Lu-PSMA-617 Radiopharmaceutical Therapy.
- Yadav S, Lowery B, Tuchayi AM, Jiang F, Saelee R, Aggarwal RR, Juarez R, Flavell RR, Hope TA.
- J Nucl Med. 2024 Sep 3;65(9):1395-1401. doi: 10.2967/jnumed.124.267955.
- PMCID: PMC13671392
Yadav S, et al.J Nucl Med. 2024.PMCID: PMC13671392 -
Development of a 213Bi-Labeled Pyridyl Benzofuran for Targeted α-Therapy of Amyloid-β Aggregates.
- Bender AA, Kirkeby EK, Cross DJ, Minoshima S, Roberts AG, Mastren TE.
- J Nucl Med. 2024 Sep 3;65(9):1467-1472. doi: 10.2967/jnumed.124.267482.
- PMCID: PMC13671393
Bender AA, et al.J Nucl Med. 2024.PMCID: PMC13671393